Abstract
Despite that the large, diversified group known as vascular anomaly represents vascular tumors and vascular malformations together, the authors successfully clarified different outcomes of sirolimus with these two entirely different groups of vascular disorders.1 Indeed, vascular tumors/hemangioma are the outcome of increased neoplastic endothelial cell proliferation, but vascular malformations are the outcome of the defective development of any part of the circulation system during embryogenesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
